Вибір схеми лікування мультирезистентного туберкульозу — from resistance confirmation through extended susceptibility testing to modern all-oral regimen selection
Multidrug-resistant tuberculosis (MDR-TB) is defined as Mycobacterium tuberculosis resistant to at least rifampin and isoniazid, the two most powerful first-line anti-TB drugs. Rapid molecular diagnostics such as Xpert MTB/RIF Ultra can detect rifampin resistance directly from sputum within two hours, while isoniazid resistance and confirmatory phenotypic culture typically follow. Confirming MDR status is the essential gateway step: it redirects the patient away from standard first-line therapy — which would fail and could amplify resistance — toward a specialized second-line pathway.
Rifampin and isoniazid are the backbone of standard first-line TB treatment because of their high early bactericidal activity and sterilizing power against slow-growing and dormant bacillary populations. Resistance to rifampin alone is used clinically as a strong proxy for MDR-TB, because rifampin resistance-conferring mutations in the rpoB gene are very frequently accompanied by isoniazid resistance (mutations in katG or the inhA promoter) due to shared selection pressure from inadequate or interrupted treatment, poor drug quality, or transmission of already-resistant strains.
Once rifampin resistance is detected, the patient is classified as having rifampin-resistant TB (RR-TB) and managed under MDR-TB treatment protocols pending full confirmation, because waiting for complete phenotypic results before acting would allow ongoing transmission and disease progression on a regimen that cannot succeed.
Detecting resistance early — at the point of first diagnosis rather than after first-line treatment failure — is one of the single most important levers for improving MDR-TB outcomes and limiting onward transmission of drug-resistant strains.
Rapid molecular assays (Xpert MTB/RIF Ultra, line probe assays) detect specific resistance-conferring mutations directly from sputum, delivering results in hours rather than weeks. They dramatically shorten the time from presentation to appropriate treatment initiation, which is critical both for individual outcomes and for reducing community transmission of resistant strains.
Phenotypic culture-based drug susceptibility testing remains the reference standard: it grows the organism in the presence of the drug and directly observes whether growth is inhibited. It is slower (weeks) but captures resistance mechanisms that molecular probes might miss, and it is essential for verifying molecular results and for testing drugs where reliable molecular targets are not yet established.
In practice, most MDR-TB programs use molecular testing to confirm rifampin resistance rapidly and start treatment, then send an isolate for full phenotypic and/or sequencing-based extended DST to refine the regimen once results return.
Once MDR-TB is confirmed, the isolate must be tested against fluoroquinolones and other second-line and newer agents (including injectable agents historically, and now bedaquiline and linezolid) to determine exactly which drugs remain active. This extended susceptibility profile is the single most important input for regimen construction: fluoroquinolone susceptibility in particular determines whether a patient qualifies for the shorter modern regimens or requires a longer individualized approach.
Fluoroquinolones (levofloxacin, moxifloxacin) are the most important companion drugs in modern MDR-TB regimens because of their potent bactericidal and sterilizing activity. Whether the infecting strain remains susceptible to fluoroquinolones is the single biggest determinant of regimen eligibility:
• Fluoroquinolone-susceptible MDR/RR-TB: eligible for the shorter, all-oral modern regimens built around fluoroquinolones plus bedaquiline and companion drugs. • Fluoroquinolone-resistant MDR/RR-TB (this pattern is termed pre-XDR-TB): fluoroquinolones can no longer anchor the regimen, so patients typically require a longer, individualized regimen built from remaining active drugs, guided by the complete susceptibility panel.
Extended DST also evaluates susceptibility to bedaquiline and linezolid; resistance to both of these plus fluoroquinolone resistance defines extensively drug-resistant TB (XDR-TB) under the WHO 2021 definition — the most difficult-to-treat resistance pattern, requiring the most individualized and intensive regimens.
Extended DST combines several complementary methods:
• Line probe assays (LPAs): detect specific mutations associated with fluoroquinolone and second-line injectable resistance directly from sputum or culture, with results in 1–2 days. • Targeted next-generation sequencing: increasingly used to simultaneously profile resistance-associated mutations across many genes and drug classes in a single assay, shortening the time to a complete resistance map. • Phenotypic liquid or solid culture DST: remains necessary for drugs without well-validated molecular targets, and for confirming borderline or discordant molecular results.
The faster this full profile is available, the sooner clinicians can construct an evidence-based regimen rather than starting empirically and adjusting later — a delay that risks both suboptimal treatment and continued transmission of a strain whose true resistance pattern is still unknown.
A patient whose isolate is fluoroquinolone-susceptible and shows no bedaquiline or linezolid resistance is generally the ideal candidate for a shorter, all-oral modern regimen — while any fluoroquinolone resistance redirects treatment toward a longer, individualized regimen built from the remaining active drugs.
For decades, MDR-TB treatment meant 18–24 months of therapy including painful daily injectable agents with significant toxicity (ototoxicity, nephrotoxicity). The introduction of bedaquiline, pretomanid, and linezolid, combined with rigorous clinical trials (STREAM, Nix-TB, ZeNix, TB-PRACTECAL), has transformed the field: WHO now recommends shorter, all-oral regimens such as BPaLM (bedaquiline–pretomanid–linezolid–moxifloxacin) for eligible patients, replacing injectable-containing regimens as the preferred first option.
Three relatively new or repurposed agents anchor modern regimens:
• Bedaquiline (BDQ): a diarylquinoline that inhibits mycobacterial ATP synthase, active against both replicating and dormant bacilli, with a long half-life allowing sustained exposure. • Pretomanid (Pa): a nitroimidazooxazine that disrupts cell wall synthesis and generates reactive nitrogen species under anaerobic conditions, developed specifically for drug-resistant TB. • Linezolid (LZD): an oxazolidinone protein synthesis inhibitor with potent activity but a narrower safety margin (myelosuppression, peripheral neuropathy) requiring dose and duration management.
Combined with a fluoroquinolone (moxifloxacin) in the BPaLM regimen, these drugs replaced the traditional cocktail of injectable aminoglycosides/capreomycin plus multiple weaker oral agents, cutting treatment duration roughly in half while improving tolerability and outcomes.
Several landmark trials established the evidence base for all-oral shorter regimens:
• Nix-TB and ZeNix: established bedaquiline–pretomanid–linezolid (BPaL) as effective for highly resistant (including XDR) TB, with ZeNix optimizing linezolid dosing to reduce toxicity while preserving efficacy. • TB-PRACTECAL: a randomized controlled trial that added moxifloxacin (BPaLM) for fluoroquinolone-susceptible MDR/RR-TB, showing roughly 89% favorable outcomes in six months versus lower success and much longer duration with standard-of-care regimens, leading WHO to recommend BPaLM as a preferred option.
Eligibility for these regimens depends critically on the extended susceptibility profile established in the prior stage: fluoroquinolone resistance excludes moxifloxacin from the combination and generally shifts the patient to a longer, individualized regimen built from remaining active drugs.
The shift from ~18–20 month injectable-containing regimens to ~6 month all-oral regimens represents one of the largest single improvements in MDR-TB care in the modern treatment era — but it only applies to patients whose resistance profile keeps fluoroquinolones and the core modern drugs active.
Treatment duration in MDR-TB is not one-size-fits-all: eligible patients on modern all-oral regimens complete therapy in roughly 6–9 months, while patients with more extensive resistance, contraindications to core drugs, or other complicating factors require an individualized regimen lasting roughly 18–20 months. Both pathways demand disciplined clinical, laboratory, and microbiological monitoring to detect toxicity early, confirm bacteriological response, and catch emerging resistance or treatment failure.
Shorter modern regimen (~6–9 months): monitoring is described as standard intensity — routine monthly clinical review, sputum smear/culture conversion tracking, and periodic safety labs (liver function, complete blood count for linezolid-related myelosuppression, ECG for QT prolongation risk with bedaquiline and moxifloxacin). Because the regimen composition is fixed and well-studied, monitoring follows a standardized schedule.
Longer individualized regimen (~18–20 months): monitoring is enhanced because the drug combination is tailored to a more complex resistance profile, often incorporating less-studied companion drugs, higher cumulative toxicity risk, and a longer window during which resistance could emerge or evolve further. Enhanced monitoring includes more frequent culture and susceptibility reassessment, closer safety surveillance, and more frequent multidisciplinary case review.
Across both pathways, monitoring integrates several data streams:
• Bacteriological response: monthly sputum smear microscopy and culture to document conversion from positive to negative, the key marker that treatment is working and infectiousness is declining. • Clinical response: weight gain, symptom resolution, chest imaging trends. • Safety monitoring: baseline and periodic ECG (QT interval, given bedaquiline and fluoroquinolone risk), liver enzymes, renal function, and — for linezolid-containing regimens — complete blood counts and neurologic exams to catch myelosuppression or peripheral/optic neuropathy early enough to adjust dosing rather than stop treatment. • Adherence support: given the long duration of even the "short" regimen, directly observed or digitally supported adherence programs remain essential to prevent interruptions that could allow resistance to worsen.
Enhanced monitoring for longer, more complex regimens is not just about the longer calendar duration — it reflects the higher stakes of a resistance profile with fewer effective drugs remaining, where early detection of toxicity or non-response has an outsized impact on the patient's final outcome.
Every MDR-TB patient who completes treatment successfully achieves two things at once: a personal cure, and the interruption of a transmission chain that is unusually difficult to treat once it spreads to a new host. Because MDR-TB is harder, longer, and more expensive to cure than drug-susceptible TB, each successful treatment has an outsized public health value — and the shift to modern shorter regimens has measurably improved both individual success rates and program-level capacity to treat more patients.
Untreated or inadequately treated MDR-TB patients remain infectious for longer than drug-susceptible TB patients, because the standard first-line drugs that would normally suppress bacillary load quickly are ineffective against the resistant strain. Every additional week of untreated or mistreated infectiousness is an opportunity for household and community transmission of an already drug-resistant strain — meaning newly infected contacts may acquire MDR-TB directly (primary resistance) without ever having been treated themselves.
This is why rapid confirmation (Stage 1), precise resistance mapping (Stage 2), and prompt initiation of an effective regimen (Stages 3–4) compound into a public health benefit far beyond the individual patient: faster, more effective treatment shortens the infectious period and directly reduces the number of secondary MDR-TB infections seeded in the community.
Historically, MDR-TB treatment success rates hovered around 55–60% globally, weighed down by long, toxic, injectable-containing regimens that many patients could not complete due to side effects, cost, or the sheer burden of nearly two years of therapy. Loss to follow-up and treatment discontinuation were major drivers of poor outcomes — and every incomplete or interrupted course carried the additional risk of amplifying resistance further.
Modern all-oral regimens address multiple failure points simultaneously: shorter duration improves completion rates, elimination of injectable agents removes a major source of toxicity and treatment-limiting side effects, and the potency of bedaquiline-based combinations improves bacteriological cure rates. Trial data for regimens like BPaLM report success rates approaching 85–90% in eligible patients — a substantial improvement that translates directly into fewer relapses, fewer amplified-resistance cases, and fewer onward transmissions.
Because MDR-TB is disproportionately costly and difficult to treat, the shift toward shorter, more effective all-oral regimens does not just improve individual outcomes — it expands how many patients a health system can successfully treat with the same resources, compounding the public health impact of each averted transmission chain.